SRTS

Image source: The Motley Fool. Thursday, Aug. 13, 2026 at 4:30 p.m. ET Chairman and Chief Executive Officer - Joe Sardano President, Chief Commercial Officer, and General Counsel - Michael Sardano Chief Financial Officer - Javier Rampolla Operator: Please note this event is being recorded. I would now like to turn the conference over to Alex Sharif with New Street Investor Relations. Please go ahead. Alex Sharif: Good afternoon, and thank you all for joining today's call to discuss Sensus Healthcare's second quarter 2026 financial results. Joining me from Sensus are Joe Sardano, Chairman and Chief Executive Officer; Michael Sardano, President, Chief Commercial Officer, and General Counsel; and Javier Rampolla, Chief Financial Officer. As a reminder, some of the matters that will be discussed during today's call contain forward-looking statements within the meanings of federal securities laws. All statements other than historical facts that address activities Sensus Healthcare assumes, plans, expects, believes, intends, or anticipates, and other similar expressions, will, should, or may occur in the future are forward-looking statements. The forward-looking statements are management's beliefs based upon current available information as of the date of this conference call, August 13, 2026. Sensus Healthcare undertakes no obligations to revise or update any forward-looking statements except as required by law. All forward-looking statements are subject to risks and uncertainties as described in the company's Forms 10-K, 10-Q, and other SEC filings. During today's call, references will be made to certain non-GAAP financial measures. Sensus believes these measures provide useful information for investors, yet they should not be considered as a substitute for GAAP, nor should they be viewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in today's press release. With that, I'd like to turn the call over to Joe Sardano. Joe? Joe Sardano: Thank you, Alex, and good afternoon, everyone. We appreciate you joining us today. I'll start with the issue that had the biggest impact on our second quarter financial results. During the quarter, we secured equipment orders that we expected to be recognized in Q2. Third-party financing approval was not completed before June 30th, as was promised several times, which prevented us from recognizing 19 units and related revenue in the quarter. The good news is that the eight units in question have since been approved, and the related revenue will be recognized in the third quarter. This bank clearly overcommitted while attempting to impress us to earn and further gain ongoing business from us. They were unable to execute on their promises. We will no longer be working with this bank. More importantly, our commercial momentum strengthened during the quarter. At the beginning of the year, we laid out five priorities for 2026. Education and training, which is ongoing. Accelerating customer adoption, which is occurring. Expanding recurring revenue, broadening our commercial reach, and driving Sensus towards sustainable profitability. We spent much of the first half educating the market around the new CPT codes and helping physicians understand what the new reimbursement environment means for their practices. We are now seeing that work translate into commercial momentum. Our pipeline is stronger. We are seeing more inbound interests. We are engaging with a broader range of customers, including independent dermatology practices, larger physician groups, and health systems. We are increasingly seeing opportunities with larger organizations that have the potential to adopt SRT across multiple locations during our multiple models. That is the future of our business. We are not looking simply to replace revenue from one customer with revenue from another. We are building a broader, more diversified customer base that can support sustainable, more predictable growth in a wider geography. The dedicated CPT codes remain a major catalyst for that transition. Physicians now have greater reimbursement clarity and a much better understanding of the economics associated with providing SRT as a non-invasive alternative to Mohs surgery. As practices gain experience with the codes and see reimbursement working in the real world, the conversation increasingly moves from whether they should consider SRT to how they want to incorporate it in their practices. They are also seeing increasing utilization within our Fair Deal Agreement program. For larger groups in particular, the shared service model remains an attractive way to bring SRT into multiple practices while allowing us to participate directly in treatment utilization. At the same time, we continue to see customers evaluating direct ownership as they understand the economics under the new reimbursement environment. Internationally, we are also seeing growing interest, particularly across Asia Pacific. Michael spent considerable time in the region during the quarter, including Australia, and he will talk more about what we are seeing there in a moment. We entered the second half with considerably more commercial activity than we had entering the year. Our job now is to convert that activity into revenue, and that is exactly where our focus is. With that, I will turn the call over to Michael to provide more detail on what we are seeing in the market and how we are converting these opportunities. Michael? Michael Sardano: Thanks, Joe. I would like to start by giving some color on what we are actually seeing in the market, as the nature of our customer conversations has changed considerably since the beginning of the year. When the dedicated CPT code took effect January 1, our first job was education. Physicians needed to understand the codes, understand the economics, and most importantly, see that reimbursement was actually being paid out. That conversation has changed. Increasingly, we are no longer explaining whether reimbursement works. We are speaking with practices about how they want to bring SRT in. We are seeing growing engagement across independent dermatology practices, larger physician groups, and healthcare systems. Our pipeline strengthened during the quarter as a result of physician education, inbound customer inquiries, and follow-up from the commercial initiatives we have undertaken throughout the year. Importantly, we are increasingly engaging with larger physician organizations and healthcare systems. These opportunities naturally take longer to develop than a single practice sale, but the potential is also much greater because one relationship can ultimately represent multiple locations and multiple systems. We are spending more time with these organizations because we believe they can become an important part of the next phase of Sensus' growth. Customers also have more ways than ever to access our technology. They can purchase a system outright, utilize financing, enter into a rental arrangement, or participate in our Fair Deal Agreement program. Having those different pathways allows us to meet customers where they are and removes barriers that historically may have delayed adoption. Internationally, I spent a significant amount of time during the quarter developing our opportunities across the Asia-Pacific, particularly in Australia, New Zealand, China, and Hong Kong. We're seeing growing physician interest in SRT and believe there are attractive opportunities to build the business in these markets over time. China is as strong as ever, but Australia, in particular, has generated strong engagement in just the two conferences that we have attended, and we are actively developing relationships that can support our commercial presence there. To give you some facts, nearly 70% of all Australians will have skin cancer before the age of 70, making it the highest rate of skin cancer on Earth. New Zealand trails close behind, with no other country anywhere near them. This is a market that is prime for growth in SRT. We are going to be disciplined about international expansion, but we see it as another meaningful avenue for diversifying the Sensus business. Our priorities for the second half are straightforward. Convert the pipeline, expand adoption across a broader customer base, increase utilization of the systems already in the field, and give customers the flexibility they need to bring SRT into their practices. We have considerably more opportunities in front of us today than we did at the beginning of the year. Now it's about conversion. With that, I'll turn the call over to Javier for a review of the financials. Javier. Javier Rampolla: Thank you, Michael, and good afternoon, everyone. I will briefly review our financial results for the second quarter of 2026. Revenue for the quarter was $2.3 million, compared with $7.3 million in the prior year period, a decrease of approximately $5 million. The year-over-year decrease was primarily driven by a lower number of units sold, with 11 units sold during the second quarter of 2026, including Fair Deal Agreements and rentals, compared with 19 units during the second quarter of 2025. Revenue associated with Fair Deal Agreements and rentals is recognized over the term of the agreement rather than at the time of the shipment. Cost of sales was $1.5 million, compared with $4.4 million in the prior year period. The decrease was primarily related to lower number of units sold. Gross profit was approximately $0.8 million, compared with $2.9 million during the second quarter of 2025. Gross margin was 34.8% compared with 39.7% in the prior year period. The decrease in gross profit and margin was primarily driven by product mix, including a higher proportion of international shipments, which carry low average selling prices, as well as costs associated with the new system placement under our Fair Deal Agreement program. As utilization increases, we expect those placements to contribute revenue over future periods. Turning to operating expenses. General and administrative expense was $1.8 million compared with $2 million in the prior year period. The decrease was primarily attributable to lower compensation costs, partially offset by higher professional fees. Selling and marketing expense was $1.1 million compared with $1.4 million in the prior year period. The decrease was primarily driven by lower trade show expenses, commission expenses, and clinical research costs. Research and development expense was also $1.1 million compared with $1.5 million in the prior year period. The decrease primarily reflected lower product development costs related to next-generation system and reduced headcount. Adjusted EBITDA for the second quarter of 2026 was -$3 million compared with -$1.8 million for the second quarter of 2025. Adjusted EBITDA, a non-GAAP financial measure, is defined as earnings before interest, taxes, depreciation, amortization, and stock compensation expense. Please see our earnings release issued earlier today for a reconciliation between GAAP and non-GAAP financial measures. Other income was approximately $0.1 million compared with approximately $2.2 million in the prior year period and relates primarily to interest income. Net loss for the quarter was $8.7 million or $0.53 per share compared with a net loss of $1 million or $0.06 per share during the second quarter of 2025. The second quarter of 2026 included a $5.7 million valuation allowance against net deferred tax assets. Turning to the balance sheet. We ended the quarter with $15.2 million in cash and cash equivalents compared with $18.3 million as of March 31st, 2026. The company had no outstanding borrowings under its revolving credit as of June 30. Inventory was $18.4 million as of June 30 compared with $16.5 million as of March 31. While prepaid inventory was approximately $0.6 million as of June 30. Our inventory position provides us with the ability to support both direct equipment sales and continued placements as we work to convert the commercial pipeline. Before turning the call back to Joe, I'd like to provide some perspective on the second half. As we have discussed, second quarter results were affected by timing of revenue recognition on eight units. That equipment now has been sold and the related revenue recognized in the quarter. We also entered the quarter with continued commercial activity across our domestic and international markets. As a result, we continue to remain confident in our ability to deliver stronger performance during the second half of 2026. With that, I'll turn the call back to Joe. Joe Sardano: Thank you, Javier and Michael. The message I want to leave with you today is straightforward. We spent the first half building the foundation of this new reimbursement environment, and we are now seeing that translate into stronger commercial momentum. Our pipeline is growing, our customer base is broadening, utilization is increasing, and we are working closely with larger organizations in the U.S. as well as new opportunities internationally. We remain focused on the same five priorities we established at the beginning of the year: ongoing education and training, accelerating customer adoption, expanding recurring revenue, broadening our commercial reach, and driving Sensus toward profitability. We remain confident that the second half of 2026 will be stronger than the first, and our focus is on execution and conversion. Thank you for your continued support. Now we are happy to take questions. Operator? Operator: Thank you. We will now begin the question and answer session. To ask a question, you may press star then one on your telephone keypad. If you are using a speakerphone, please pick up your handset before pressing the keys. To withdraw your question, please press star then two. The first question comes from Anthony Vendetti from Maxim Group. Please go ahead. Anthony Vendetti: Thanks. I just want to focus on those eight units. Sounds like, obviously didn't have a good situation with that one particular bank that was responsible for financing those eight. Joe, I thought you mentioned 19 units. Were you talking about the 19 units that were sold in second quarter 2025? And these were the only eight units that were shifted into the third quarter? Joe Sardano: No. This relates to the 11 units that we booked and have marked as booked for Q2. Had we been able to get this bank to meet the deadline, as they promised, that would have been eight more. We would have had 19 units for the quarter. Anthony Vendetti: Got it. Joe Sardano: That would be relative to what we did in the first quarter, which was 14. So we would have had 19. Those eight units now have fallen into the third quarter. They have already been approved, sold, and it did not take long for a bank to come in and get it done for us. Anthony Vendetti: Okay. So you had another bank do that. On those eight units, I do not know if they were just SRT-100s or SRT-100+. Should we assume an ASP on those on an aggregate of around $200,000 each? Is that about right, or was it a little more than that? Joe Sardano: They were all the, not the Visions, they were all the 100s, and we are expecting to have an average selling price of closer to $250,000. Anthony Vendetti: $250,000. Okay, great. Joe Sardano: Yeah. Anthony Vendetti: Okay. Then you are talking about delivering a strong second half performance. It sounds like, in terms of your at least pipeline of activity, you are seeing an increased level of interest. When you look at that pipeline, are these earlier conversations, or is that pipeline filled with customers that are about to place orders and you are just looking to cross the T's and dot the I's? Or is this pipeline just starting to build for the second half? Joe Sardano: The pipeline really started from day one of this year when we started going through the education and training process of what these new CPT codes represented. It is a combination of a lot of new customers, but a lot of customers that we have been talking to over the last six to nine months, quite frankly. So, we are excited for that pipeline, and I think that we are going to see a lot of that come to fruition here in the second half, which was the reason why we always said that we were going to get better as the year went on. Anthony Vendetti: Okay, then lastly, without naming the largest customer you used to have, is that customer still not purchasing any units from you? Maybe just an update on whether or not you think there could be some units purchased by that former customer in the second half of 2026. Joe Sardano: No units are being purchased by them, and I would say that we're not expecting any units to be purchased by them. I think that they're still going through what they have to discuss amongst themselves to reevaluate their models. Anthony Vendetti: Understood. Then maybe one last one on the Fair Deal Agreement. As you look at the pipeline, are most of these potential contracts going to be under the Fair Deal Agreement? I know internationally, they're usually sales. So if we had a look at the revenue mix, how would you very broadly break that out in terms of expectations? Joe Sardano: I think we're seeing the recurring revenue model at about a 50/50 pace with outright purchase. We still have a lot of customers that want to buy the units, and we still have a lot of the larger groups that only want to go through the recurring model phase. So that's what we're experiencing right now. So I think that bodes well for not just the present, but also the future. Anthony Vendetti: Okay, great. Thanks for all that color, and I'll hop back in the queue. Joe Sardano: Thanks, Anthony. Michael Sardano: Thanks, Anthony. Javier Rampolla: Thank you, Anthony. Operator: As a reminder, if you have a question, please press star one. The next question comes from Ben Haynor from Lake Street Capital Markets. Please go ahead. Ben Haynor: Good afternoon, gentlemen. Thanks for taking the questions. Joe Sardano: Hey, Ben. Ben Haynor: Just curious on 11 sales, you mentioned also that about half and half are kind of sales versus recurring/rental. How did those shake out? I apologize if I missed this, between rental sales, Fair Deal Agreement. Joe Sardano: Out of the 11, six were direct sales. Ben Haynor: Okay. Got it. You had 14 in Q1, you would have had 19 in Q2. Maybe I misread the way you couched it earlier this year, but my recollection was that you expected to have more units each quarter sequentially throughout the year. Is that still the case, and should we expect 20+ units in Q3 and Q4? Joe Sardano: Very clear, yes. I appreciate you looking at that math that way, because that is exactly the way we are looking at it. We are expecting a nice third quarter to come from all of it. Ben Haynor: Okay, great. On the Sensus Link activations, anything you can discuss there? Joe Sardano: We are seeing a lot of activity on it. We are making some sales on it, so that continues to increase and contribute to the recurring revenue piece. Michael? Michael Sardano: Ben, I just add color what Joe said. It is a great question. All of the new customers that are coming in to do either a direct purchase or recurring revenue are getting Sensus Link. Almost every single one of them. I have not had one that has not. As far as the expansion Sensus Link, we have hired inside salespeople to go and call current customers that have an SRT-100 or a Vision out in the field, and we are actively trying to get as many people on Sensus Link as possible. From a percentage standpoint and from a margin standpoint, it is a very big growth area that I think that we are very excited about expanding. Ben Haynor: Does that become meaningful, you think, later this year, or does it take a couple few quarters to get people up and running, or? Michael Sardano: Yeah, it is going to build, and obviously, being a software, it is a monthly type charge. It is a smaller number, but margins are much larger. So it is going to be meaningful, and it is going to get the user experience, kind of like, I always analogize to cars, pardon me, but if you are driving around in your car from 10 years ago, you do not have anything other than maybe OnStar that has an experience of software with it. If you drive a new-age Tesla, everyone that drives a Tesla will know that there is constantly software updates, and the user interface and the user interaction is just much different. It is like playing with a computer and downloading the new app or downloading the new software. It really changes the whole car experience, and that is what we are trying to do with our SRT devices. It keeps the user engaged daily, and also it helps the user operate much, much easier. Ben Haynor: Okay, great. That sounds pretty slick. Lastly on the kind of post reimbursement, I know the hospital reimbursement, you commented in the press release is up. Anything on the physician fee schedule? I know dermatology, I think, took a hit overall. What are you guys seeing there? Michael Sardano: Yeah. The hospital proposed physician fee schedule, level one radiation, which affects SRT, anything under 150 kV, that is being proposed to increase 26%. As far as anything dermatology, nothing that I am aware of is hindering anything from dermatology. We just got the new code started January 1. Ben Haynor: Okay, great. Well, thanks for taking the questions, gentlemen. Joe Sardano: Thanks, Ben. Operator: This concludes our question and answer session. I would like to turn the conference back over to management for closing remarks. Joe Sardano: Okay. Well, thank you everybody for joining us today. Again, we have outlined what we did here in the second quarter, and we are very excited for our third and fourth quarters coming up. We look forward to touching base with you again at the end of the third quarter during the call at that time. In the meantime, stay healthy and we look forward to talking to you then. Thank you. Operator: The conference is now concluded. Thank you for attending today's presentation. You may now disconnect. Before you buy stock in Sensus Healthcare, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Sensus Healthcare wasn’t one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $432,621!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,335,314!* That performance is why people listen. With a track record of beating the S&P 500 by nearly 5x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul. See the 10 stocks » *Stock Advisor returns as of August 20, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Sensus (SRTS) Q2 2026 Earnings Call Transcript was originally published by The Motley Fool

This article first appeared on GuruFocus. Release Date: August 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Sensus Healthcare Inc (NASDAQ:SRTS) secured 8 equipment orders that were delayed in Q2 due to third-party financing issues, and these have since been approved and will be recognized as revenue in Q3. The company's commercial momentum strengthened during Q2, with a stronger pipeline, increased inbound interest, and engagement with a broader range of customers including larger physician groups and health systems. The new dedicated CPT codes for SRT are driving adoption, as physicians now have greater reimbursement clarity and are moving from 'whether' to 'how' to incorporate SRT into their practices. Sensus Healthcare Inc (NASDAQ:SRTS) is seeing growing international interest, particularly in Australia, which has the highest skin cancer rate globally, presenting a significant market opportunity. The company is expanding its recurring revenue streams through the Fair Deal Agreement program and CensusLink software, with all new customers adopting CensusLink and inside sales efforts targeting existing customers. Sensus Healthcare Inc (NASDAQ:SRTS) experienced a significant revenue decline in Q2 2026, with revenue of $2.3 million compared to $7.3 million in the prior year period, due to lower unit sales. The company faced a financing issue with a third-party bank that failed to complete approvals on time, preventing the recognition of 19 units in Q2 and leading to a decision to no longer work with that bank. Gross margin decreased to 34.8% from 39.7% in the prior year, driven by product mix including higher international shipments with lower average selling prices and costs associated with new system placements. Adjusted EBITDA was negative $3 million in Q2 2026, worse than the negative $1.8 million in Q2 2025, indicating continued operational losses. The company recorded a net loss of $8.7 million in Q2 2026, including a $5.7 million valuation allowance against deferred tax assets, and cash decreased to $15.2 million from $18.3 million at the end of Q1. Warning! GuruFocus has detected 4 Warning Signs with SRTS. Is SRTS fairly valued? Test your thesis with our free DCF calculator. Q: Can you clarify the impact of the eight units that were delayed from Q2 and confirm the expected average selling price (ASP) for these units?A: Joe Cordano, Chairman and CEO, clarified that the company had booked 11 units for Q2, and had the third-party financing bank met its promised deadline, they would have recognized 19 units for the quarter. The eight delayed units have since been approved and sold, with revenue now recognized in Q3. He confirmed all eight were SRT-100 Vision systems, with an expected ASP of approximately $250,000 each. Q: Given the stronger pipeline, are these conversations early-stage or are they close to closing? What is the expectation for unit sales in Q3 and Q4?A: Joe Cordano stated the pipeline has been building since the start of the year through education on new CPT codes, combining new customers with those in discussions for six to nine months. He expressed confidence in converting this pipeline in the second half, reiterating the expectation for sequential unit growth, with a "nice third quarter" anticipated. Q: Is the former largest customer still not purchasing units, and do you expect any purchases from them in the second half of 2026?A: Joe Cordano confirmed that no units are being purchased by the former largest customer, and the company does not expect any purchases from them in the second half. He noted that this customer is still internally evaluating and reevaluating their business models. Q: How is the revenue mix shaping up between outright purchases and recurring revenue models like the Fair Deal Agreement (FDA)?A: Joe Cordano indicated the mix is currently about 50-50 between recurring revenue models and outright purchases. He noted that while many customers still prefer to buy units outright, larger groups increasingly favor the recurring model, which bodes well for both present and future revenue stability. Q: Of the 11 units sold in Q2, how many were direct sales versus recurring/rental agreements?A: Joe Cordano specified that out of the 11 units sold in Q2, six were direct sales, with the remaining five falling under recurring revenue or rental agreements. Q: Can you provide an update on CensusLink activations and its contribution to revenue?A: Joe Cordano noted strong activity and sales for CensusLink, contributing to recurring revenue. Michael Cordano, President and Chief Commercial Officer, added that nearly all new customers are adopting CensusLink, and the company has hired inside salespeople to expand adoption among existing field customers. He highlighted it as a high-margin growth area, though revenue will build gradually as it is a monthly subscription model. Q: What is the outlook for the hospital physician fee schedule and any impacts on dermatology reimbursement?A: Michael Cordano reported that the proposed hospital physician fee schedule for level one radiation (under 150 kV, which includes SRT) is set to increase by 26%. He noted no hindering changes for dermatology, especially given the new dedicated CPT codes that took effect January 1. Q: Can you elaborate on the international opportunities, particularly in Australia and the Asia Pacific region?A: Michael Cordano highlighted significant time spent developing opportunities in Australia, New Zealand, China, and Hong Kong. He noted that nearly 70% of Australians will develop skin cancer before age 70, the highest rate globally, making it a prime market for SRT. The company is actively developing relationships to support a commercial presence there, though expansion will be disciplined. Q: What caused the decline in gross margin, and how should we view it going forward?A: Javier Rompola, CFO, attributed the gross margin decline to product mix, including a higher proportion of international shipments with lower ASPs, and costs associated with new system placements under the Fair Deal Agreement program. He noted that as utilization increases, these placements are expected to contribute revenue over future periods. Q: Can you provide more color on the $5.7 million valuation allowance against deferred tax assets and its impact on net loss?A: Javier Rompola explained that the Q2 2026 net loss of $8.7 million included a $5.7 million valuation allowance against net deferred tax assets. This non-cash charge significantly impacted the bottom line, with net loss per share of $0.53, compared to a net loss of $0.06 per share in Q2 2025. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Second quarter revenue was significantly impacted by a third-party bank's failure to complete financing approvals for eight units by the quarter-end deadline, despite multiple promises of execution. Management has terminated the relationship with the failing bank and successfully secured alternative financing for the delayed units, which have already been recognized in the third quarter. The first half of 2026 focused heavily on market education regarding new CPT codes, helping physicians transition from questioning reimbursement validity to determining how to integrate SRT into their practices. Commercial momentum is shifting toward larger physician groups and health systems that offer the potential for multi-location adoption and more predictable, diversified growth. The company is seeing a balanced 50/50 split between direct equipment sales and recurring revenue models, such as the Fair Deal Agreement, which lowers adoption barriers for larger organizations. International interest is accelerating, particularly in Australia and New Zealand, where skin cancer rates are the highest globally and physician engagement has been strong at recent conferences. Management expects sequential unit growth to continue through the second half of 2026, targeting 20-plus units per quarter for Q3 and Q4. The company is prioritizing the conversion of a pipeline built over the last six to nine months, driven by the clarity provided by the new reimbursement environment. Expansion of recurring revenue remains a top priority, supported by the deployment of inside sales teams to activate Sensus Link software across the existing installed base. Proposed hospital physician fee schedules suggest a 26% increase for level one radiation., which management believes will further support the economic case for SRT adoption. Strategic focus remains on driving the company toward sustainable profitability through a mix of high-margin software services and expanded domestic and international system placements. The second quarter results included a $5.7 million valuation allowance against net deferred tax assets, contributing to the reported net loss. Gross margins were pressured by product mix, specifically a higher proportion of international shipments with lower average selling prices and costs related to new Fair Deal Agreement placements. Management explicitly stated they no longer expect any unit purchases from their formerly largest customer as that organization reevaluates its internal business models. Inventory levels were maintained at $18.4 million to ensure the ability to support both direct sales and rapid placements as the commercial pipeline converts. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management clarified that had the financing been approved on time, the company would have reported 19 units for Q2, representing sequential growth from 14 units in Q1. The eight units were SRT-100 models with an expected average selling price of approximately $250,000 each. Current demand is split roughly 50/50 between outright purchases and recurring revenue models like the Fair Deal Agreement. Larger physician groups are showing a preference for recurring models, while many individual practices still opt for direct ownership to capture full reimbursement economics. Sensus Link is being included in almost every new customer agreement, and a dedicated inside sales team is targeting the legacy installed base for activations. While the monthly fees are smaller than hardware sales, the software carries significantly higher margins and increases daily user engagement with the technology.

Interested in Sensus Healthcare, Inc.? Here are five stocks we like better. Second-quarter revenue fell sharply to $2.3 million from $7.3 million a year earlier, primarily because financing delays prevented recognition of eight equipment sales. Sensus expects to recognize those sales, valued at roughly $250,000 per SRT-100 system, in the third quarter. Profitability weakened, with gross margin declining to 34.8%, an adjusted EBITDA loss of $3 million, and a net loss of $8.7 million, including a $5.7 million deferred-tax valuation allowance. Cash fell to $15.2 million, although the company had no revolving-credit borrowings outstanding. Management expects a stronger second half, citing a growing pipeline, increased physician familiarity with SRT reimbursement, international opportunities, and expansion of recurring-revenue offerings such as Fair Deal Agreements and Sensus Link. A proposed 26% increase in reimbursement for certain low-energy radiation treatments could further support adoption. Sensus Healthcare (NASDAQ:SRTS) reported second-quarter revenue of $2.3 million, down from $7.3 million a year earlier, as delayed third-party financing prevented the company from recognizing revenue tied to eight equipment units before the end of June. Chairman and Chief Executive Officer Joe Sardano said the company had secured orders expected to be recognized in the second quarter, but a bank did not complete financing approvals by June 30 despite repeated assurances. Sensus has since obtained approval for the eight units through another bank and expects to recognize the related revenue in the third quarter, he said. → Lumentum Just Delivered the AI Growth Investors Wanted “We will no longer be working with this bank,” Sardano said. He clarified during the question-and-answer session that Sensus booked 11 units in the second quarter and would have recorded 19 units had the eight additional financing-backed orders closed in time. The eight units were SRT-100 systems and are expected to carry an average selling price closer to $250,000, according to Sardano. Sensus sold 11 units during the quarter, including Fair Deal Agreements and rentals, compared with 19 units in the second quarter of 2025. Of the 11 units, six were direct sales, Sardano said. Revenue from Fair Deal Agreements and rentals is recognized over the term of the arrangement rather than upon shipment. Revenue was $2.3 million, compared with $7.3 million in the prior-year quarter. Cost of sales declined to $1.5 million from $4.4 million. Gross profit was approximately $0.8 million, down from $2.9 million. Gross margin was 34.8%, compared with 39.7% a year earlier. Adjusted EBITDA loss was $3 million, compared with an adjusted EBITDA loss of $1.8 million. Net loss was $8.7 million, or $0.53 per share, compared with a net loss of $1 million, or $0.06 per share. → Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal Chief Financial Officer Javier Rampolla said the net loss included a $5.7 million valuation allowance against net deferred tax assets. Gross margin was affected by product mix, including a greater proportion of international shipments with lower average selling prices and costs associated with new Fair Deal Agreement placements. Rampolla said those placements are expected to generate revenue in future periods as utilization rises. General and administrative, selling and marketing, and research and development expenses each declined year over year, driven by factors including lower compensation, trade show, commission, clinical research, product development, and headcount costs. → AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be The company ended the quarter with $15.2 million in cash and cash equivalents, down from $18.3 million at March 31. It had no outstanding borrowings under its revolving credit facility. Inventory rose to $18.4 million from $16.5 million at the end of the first quarter. Management said its commercial pipeline strengthened as physicians gained familiarity with dedicated CPT codes that took effect Jan. 1. The company spent the first half educating physicians about reimbursement and the economics of providing superficial radiation therapy, or SRT, as a non-invasive alternative to Mohs surgery. Michael Sardano, President, Chief Commercial Officer and General Counsel, said customer discussions have increasingly shifted from whether reimbursement works to how practices can incorporate SRT. The company reported growing engagement from independent dermatology practices, larger physician groups, and healthcare systems. Management said larger organizations may take longer to develop than single-practice sales but could support adoption across multiple locations. Customers can access the company’s technology through outright purchases, financing, rentals, or Fair Deal Agreements, which are shared-service arrangements that allow Sensus to participate in treatment utilization. Joe Sardano said the current pipeline is running at roughly a 50/50 mix between recurring-revenue arrangements and outright purchases. He also said Sensus does not expect equipment purchases in the second half from a formerly large customer that is reevaluating its operating model. Management said it expects stronger results in the second half of 2026, supported by the delayed eight-unit revenue recognition and a larger commercial pipeline. Sardano said the company expects sequential unit growth and anticipated “a nice third quarter,” following 14 units in the first quarter and what would have been 19 units in the second quarter absent the financing delay. The company is also pursuing international opportunities, particularly in Australia, New Zealand, China, and Hong Kong. Michael Sardano said China remains a strong market and that Sensus has seen strong engagement in Australia after attending two conferences there. He cited high skin-cancer incidence in Australia and New Zealand as a potential opportunity for SRT adoption. Separately, management said all new customers obtaining systems through either direct sales or recurring-revenue arrangements are receiving Sensus Link, the company’s software offering. Sensus has added inside sales personnel to market the service to existing SRT-100 and Vision customers, with management describing it as a potentially higher-margin recurring-revenue opportunity. Management also noted that a proposed hospital physician fee schedule would increase reimbursement for level-one radiation, including treatments under 150 kV that affect SRT, by 26%. The company said it remains focused on education and training, accelerating customer adoption, expanding recurring revenue, broadening its commercial reach, and moving toward sustainable profitability. Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company's SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare's systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients. The company's flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Sensus Healthcare Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

Commercial Momentum Builds Following CPT Code Implementation Revenue Recognition on Eight Purchased Units Shifted to Q3 Due to Financing Approval Timing CMS Proposed 26% Increase in Hospital-Based Delivery Code, Further Strengthening the Reimbursement Outlook for SRT Customer Adoption, Pipeline Development and Commercial Expansion Advanced Across U.S. and International Markets Company Remains Focused on Delivering Strong Second Half Performance BOCA RATON, Fla., August 13, 2026--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026. Highlights included: Revenues of $2.3 million for the quarter ended June 30, 2026, a decrease of $5.0 million, from the 2025 quarter. The decrease was driven by a lower number of units sold in the 2026 quarter, resulting in part from the inability to record the sale of eight units in Q2 due to financing approval timing. This sale will be recognized in Q3. Customer adoption accelerated through expanding engagement with independent practices, larger physician groups, and health systems. Sales pipeline strengthened following CPT code implementation, supported by increasing physician education, inbound customer inquiries and commercial activity. CMS proposed a 26% increase in the hospital-based SRT delivery code, which, if finalized, would further improve provider economics and support expanded adoption of SRT across hospital and health system settings. International commercial activity expanded across key Asia-Pacific markets, including Australia and New Zealand, supporting future growth opportunities. Active website users increased 153% year-over-year. Company remains committed to delivering strong performance during the second half of 2026. Management Commentary "While our reported second quarter revenue was impacted by the timing of financing approvals for eight units, our commercial execution remained strong throughout the quarter. Those units have since been sold and related revenue will be recognized in Q3. The delayed financing approval affected the timing of revenue recognition, not customer demand or commercial execution," said Joseph Sardano, Chairman and Chief Executive Officer. "Importantly, we are seeing the benefits of the dedicated CPT codes reflected in growing physician engagement, expanding customer interest, and a strengthening sales pipeline. During the quarter, we broadened relationships with larger physician groups, increased utilization under our Fair Deal Agreement program, and advanced our commercial initiatives in both the U.S. and internationally. In addition, we were particularly encouraged by the level of engagement we experienced across key Asia-Pacific markets, including Australia and New Zealand, where growing awareness of SRT is creating attractive long-term opportunities. "We entered the third quarter with a healthy pipeline, growing customer engagement, and increasing commercial activity across both our domestic and international markets. We remain encouraged by the momentum we are seeing across the business and focused on executing against our five strategic priorities for 2026 - education and training, accelerating customer adoption, expanding recurring revenue, broadening our commercial reach, and driving Sensus toward profitability," concluded Sardano. Second Quarter 2026 Financial Results Revenues were $2.3 million for the three months ended June 30, 2026, compared to $7.3 million for the three months ended June 30, 2025, a decrease of $5.0 million, or 68.5%. The decrease in revenue was primarily driven by a lower number of units sold (11 in the three months ended June 30, 2026, including Fair Deal Agreements and rentals, compared to 19 in the three months ended June 30, 2025), reflecting no sales in the current period to a historically large customer. In addition, some systems placed during the quarter were under the Fair Deal Agreement program and rental arrangements, for which revenue is recognized over the term of the agreement rather than at the time of shipment. Cost of sales was $1.5 million for the three months ended June 30, 2026, compared to $4.4 million for the three months ended June 30, 2025, a decrease of $2.9 million, or 65.9%. The decrease in cost of sales was primarily related to the lower number of units sold. Gross profit was $0.8 million for the three months ended June 30, 2026, compared to $2.9 million for the three months ended June 30, 2025, a decrease of $2.1 million, or 72.4%. Our overall gross profit percentage was 34.8% in the three months ended June 30, 2026, compared to 39.7% in the corresponding period in 2025. The decrease in gross profit and margin was primarily driven by product mix, including a higher proportion of international shipments, which carry lower average selling prices, and costs associated with new system placements pursuant to the Fair Deal Agreements, which are recognized upfront while related revenue is recognized over the term of the agreement. General and administrative expense was $1.8 million for the three months ended June 30, 2026, compared to $2.0 million for the three months ended June 30, 2025, a decrease of $0.2 million, or 10.0%. The net decrease in general and administrative expense was primarily due to lower compensation costs, slightly offset by increases in professional fees. Selling and marketing expense was $1.1 million for the three months ended June 30, 2026, compared to $1.4 million for the three months ended June 30, 2025, a decrease of $0.3 million, or 21.4%. The decrease was primarily driven by a decrease in tradeshow expenses, commission expenses, and clinical research costs. Research and development expense was $1.1 million for the three months ended June 30, 2026, compared to $1.5 million for the three months ended June 30, 2025, a decrease of $0.4 million, or 26.7%. The decrease was primarily due to a decrease in product development costs related to next-generation systems and reduced headcount. Other income of $0.1 million and $0.2 million for the three months ended June 30, 2026 and 2025, respectively, relates primarily to interest income. The tax expense for the second quarter of 2026 includes a $5.7 valuation allowance against net deferred tax assets. Net loss was $8.7 million, or $0.53 per share, compared with net loss of $1.0 million, or $0.06 per share, for the three months ended June 30, 2025. Adjusted EBITDA for the second quarter of 2026 was negative $3 million, compared with negative $1.8 million for the second quarter of 2025. Adjusted EBITDA, a non-GAAP financial measure, is defined as earnings before interest, taxes, depreciation, amortization and stock-compensation expense. Please see below for a reconciliation between GAAP and non-GAAP financial measures, and the reasons these non-GAAP financial measures are provided. Cash, restricted cash and cash equivalents were $15.2 million as of June 30, 2026, compared with $18.3 million as of March 31, 2026. The Company had no outstanding borrowings under its revolving line of credit at June 30, 2026. Prepaid inventory was $0.6 million as of June 30, 2026, compared with $2.5 million as of March 31, 2026. Inventories were $18.5 million as of June 30, 2026, compared with $16.5 million as of March 31, 2026. Conference Call and Webcast Sensus Healthcare will host an investment community conference call today beginning at 4:30 p.m. Eastern time during which management will discuss these financial results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register can access the conference call by dialing 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). Please ask the operator to be connected to the Sensus Healthcare conference call. The call will be webcast live and can be accessed at this link or in the Investor Relations section of the Company’s website at www.sensushealthcare.com. Use of Non-GAAP Financial Information This press release contains supplemental financial information determined by methods other than in accordance with accounting principles generally accepted in the United States (GAAP). Sensus Healthcare management understands that investors and analysts use Adjusted EBITDA, a non-GAAP financial measure, in analyzing the Company’s performance. Adjusted EBITDA should not be considered a substitute for GAAP basis measures, nor should it be viewed as a substitute for operating results determined in accordance with GAAP. Non-GAAP financial measures are not formally defined by GAAP, and other entities may use calculation methods that differ from those used by Sensus Healthcare. As a complement to GAAP financial measures, management believes that Adjusted EBITDA assists investors who follow the practice of some investment analysts who adjust GAAP financial measures to exclude items that may obscure underlying performance and distort comparability. A reconciliation of the GAAP net loss to Adjusted EBITDA is provided in the schedule below. About Sensus Healthcare Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com. Forward-Looking Statements This press release includes statements that are, or may be deemed, "forward-looking statements." In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately," or "potential," or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus Healthcare, Inc., our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release as a result of the following factors, among others: the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries, including ongoing geopolitical tensions between the U.S. and China; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation (including the possibility of tariffs and fluctuations in tariffs on equipment we export or materials we import), or other aspects of our business; the performance of the Company’s information technology systems and its ability to maintain data security; the possibility that inflationary pressures continue to impact our sales; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission. To date, geopolitical uncertainties have not had any significant impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date this press release is issued, except as may be required by applicable law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260813917539/en/ Contacts Investor Relations Contact Leigh SalvoNew Street Investor [email protected]

Interested in Sensus Healthcare, Inc.? Here are five stocks we like better. Sensus Healthcare’s Q1 2026 revenue fell to $3.4 million from $8.3 million a year ago, mainly because it had no sales to its historically largest customer. Management said the underlying business looked stronger when excluding that one-off comparison. The quarter marked a major transition as new CPT reimbursement codes for superficial radiotherapy took effect on Jan. 1. Management said it spent much of the quarter educating customers, and initial reimbursement results have been positive, helping drive stronger interest and pipeline activity. The company is pushing recurring and utilization-based revenue through Fair Deal Agreement placements and the Sensus Link software platform. Sensus ended the quarter with $18.3 million in cash, no debt, and management expects sequential revenue improvement through 2026. Sensus Healthcare (NASDAQ:SRTS) said its first quarter of 2026 marked a transition period as new dedicated CPT codes for superficial radiotherapy took effect, while revenue declined from the prior year due largely to the absence of sales to its historically largest customer. Chairman and Chief Executive Officer Joe Sardano said the company is operating in a “fundamentally different environment” following the Jan. 1 implementation of dedicated reimbursement codes for superficial radiotherapy, or SRT. He said the company spent much of the quarter educating customers and prospects on the new coding structure and training them on how to use it. → Insider Sales: Top AST SpaceMobile Insider Cuts Postion Over 30% “Initial results are excellent,” Joe Sardano said, adding that customers billing CMS under the new coding are seeing reimbursements. He said the company believes physicians and patients will gain confidence that SRT is “receiving full funding.” Chief Financial Officer Javier Rampolla said first-quarter revenue was $3.4 million, compared with $8.3 million in the prior-year period. The decline was primarily attributed to the absence of sales to the company’s historically largest customer and a lower number of total units shipped. → Light Speed Returns: Corning Cashes In on NVIDIA Growth Rampolla noted that the first quarter of 2025 included a significant number of direct sales to that customer, while the 2026 quarter had no sales to that customer. Excluding sales to that customer in the prior-year period, revenue increased from $2.7 million, which Rampolla said demonstrated underlying growth from a broader customer mix. The company shipped 14 SRT systems during the quarter, including 10 direct sales and four placements under its Fair Deal Agreement program and rental arrangements. Joe Sardano said those shipments matched the fourth quarter and reflected progress in reducing historical customer concentration. → Years in the Making, AMD’s Upside Movement Has Just Begun Cost of sales was $2.4 million, down from $4 million a year earlier. Gross profit was $1 million, compared with $4.4 million, while gross margin declined to 29.2% from 52.2%. Rampolla said the margin decline was primarily driven by product mix, including a higher proportion of international shipments with lower average selling prices and costs tied to new Fair Deal Agreement placements. Net loss was $2.6 million, or $0.16 per share, consistent with the prior-year period. Adjusted EBITDA was negative $4.2 million, compared with negative $2.5 million in the first quarter of 2025. Joe Sardano outlined five priorities for 2026: educating the market on reimbursement and code usage, driving customer adoption after CPT code implementation, growing recurring and utilization-based revenue, diversifying the commercial model, and delivering sustainable profitability. He said the new reimbursement environment has improved physician economics, including an approximately 300% increase in the per-fraction delivery code. The company reported increased inquiry levels, stronger pipeline development, and greater engagement from dermatology practices and hospital systems. Michael Sardano, President, Chief Commercial Officer and General Counsel, said reimbursement clarity has changed how customers evaluate SRT. He said customers now have several adoption pathways, including outright purchases, leasing structures and the Fair Deal Agreement program. During the quarter, about 70% of systems shipped were purchased rather than placed under the Fair Deal Agreement program. “Customers now have multiple pathways to adoption,” Michael Sardano said. He added that the average breakeven for customers is now two patients per month and that the company is seeing more customers choose ownership earlier in the adoption cycle. Management emphasized the company’s effort to expand recurring revenue tied to utilization of its installed base. Joe Sardano said treatment volumes under the Fair Deal Agreement program increased 8% from the first quarter of 2025. The company ended the quarter with 18 active FDA sites and nine pending activations. Sensus also highlighted Sensus Link, a software platform intended to enhance workflow, treatment documentation and operating intelligence across the installed base. Joe Sardano said Sensus Link represents a scalable recurring revenue opportunity tied to treatment activity. During the question-and-answer session, Joe Sardano said Sensus Link is already live and “performing in several accounts.” He also discussed a radiation physics consult code that he said can be billed weekly for each patient and said the company expects to share revenue with customers through Sensus Link. Michael Sardano said total shipped systems now stand at approximately 965 units globally. He said the company expects the rollout of Sensus Link to its SRT-100 installed base to take shape this year and increase interest in SRT. Operating expenses declined across several categories. General and administrative expense was $2 million, down from $2.2 million, primarily due to lower professional fees. Selling and marketing expense was $1.7 million, down from $2.2 million, reflecting a decision to reduce trade show-related spending and focus on events with higher sales potential. Research and development expense was $1.6 million, down from $2.6 million, reflecting lower lobbying costs related to reimbursement efforts as well as reductions in headcount and next-generation product development spending. The company ended the quarter with $18.3 million in cash, no debt and inventory of $16.5 million, up from $14.6 million at Dec. 31, 2025. Rampolla said the inventory level positions the company to meet demand in coming quarters for both direct sales and Fair Deal Agreement placements. Rampolla said Sensus expects second-quarter revenue to exceed first-quarter revenue and expects revenue in the second half of 2026 to be higher than in the first half. He said the company anticipates the gross margin dynamics from the first quarter to evolve as utilization under Fair Deal Agreement placements increases and revenue is recognized over time. In response to a question from Anthony Vendetti of Maxim Group about the company’s largest customer, Joe Sardano said any return by that customer would represent upside because the company has not included that customer in its model for the year. Management also said leads from the American Academy of Dermatology annual meeting, held at the end of March, are expected to contribute to second-quarter activity. Michael Sardano said customers only began seeing explanations of benefits from the new reimbursement codes in mid-February to early March, and that proof of payment is now being used by the sales team in the market. Joe Sardano closed the call by saying management expects “each and every quarter” to be better than the previous one and reiterated the company’s objective of achieving full-year profitability. Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company's SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare's systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients. The company's flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls. The article "Sensus Healthcare Q1 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for May 2026.

Image source: The Motley Fool. Thursday, May 7, 2026 at 4:30 p.m. ET Chairman and Chief Executive Officer — Joseph C. Sardano President, Chief Commercial Officer and General Counsel — Michael J. Sardano Chief Financial Officer — Javier Rampolla Investor Relations — Leigh Salvo Operator: Welcome to Sensus Healthcare, Inc. First Quarter 2026 Financial Results Conference Call. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Leigh Salvo with New Street Investor Relations. Please go ahead. Leigh Salvo: Good afternoon. And thank you all for joining today's call to discuss Sensus Healthcare, Inc.'s First Quarter 2026 Financial Results. Joining me from Sensus Healthcare, Inc. are Joseph C. Sardano, Chairman and Chief Executive Officer, Michael J. Sardano, President, Chief Commercial Officer and General Counsel, and Javier Rampolla, Chief Financial Officer. As a reminder, some of the matters that will be discussed during today's call contain forward-looking statements within the meaning of federal securities laws. All statements other than historical facts that address activities Sensus Healthcare, Inc. assumes, plans, expects, believes, intends, or anticipates, and other similar expressions such as will, should, or may occur in the future, are forward-looking statements. The forward-looking statements are management's belief based upon current available information as of the date of this conference call, 05/07/2026. Sensus Healthcare, Inc. undertakes no obligation to revise or update any forward-looking statements except as required by law. All forward-looking statements are subject to risks and uncertainties as described in the Company's Forms 10-K, 10-Q and other SEC filings. During today's call, references will be made to certain non-GAAP financial measures. Sensus Healthcare, Inc. believes these measures provide useful information for investors, yet they should not be considered as a substitute for GAAP, nor should they be viewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in today's press release. With that, I would like to turn the call over to Joseph C. Sardano. Joe? Joseph C. Sardano: Thank you, Leigh, and good afternoon, everybody. We appreciate you joining us today. 2026 represents an important transition period for Sensus Healthcare, Inc. With the dedicated CPT codes for superficial radiotherapy now in effect as of January 1, we are operating in a fundamentally different environment than ever before. We are tasked with the responsibility of helping our entire industry pivot to the new reality. For quite some time, two factors weighed heavily on our business: customer concentration and the absence of reimbursement clarity. Today, we believe both of those factors are beginning to shift in a meaningful way. I would like to frame our discussion around five priorities that we believe will define our progress in 2026 and provide a clear framework for tracking our execution over the course of the year. Number one, educate the market on the new reimbursement and train them on how to utilize the codes. Two, drive customer adoption following CPT code implementation. Three, grow our recurring and utilization-based revenue streams. Four, diversify and strengthen the commercial model. And last, number five, deliver sustainable profitability. Our entire first quarter was dedicated to helping existing customers and new prospects better understand the new reimbursement coding. Initial results are excellent. The coding is simple and straightforward, and for those who have billed CMS under the new coding, they are already seeing a smooth transition by the payers as our users receive reimbursements. Both physicians and patients will continue to grow in confidence that SRT is receiving full funding. Which brings us to customer adoption and CPT impact. One of our strategic priorities is converting the new reimbursement environment into broader customer adoption and a more diversified installed base. During the first quarter, we began to see the benefits of the new CPT codes move from concept to commercial reality. With reimbursement now clearly defined and physician economics significantly improved, including approximately a 300% increase in the per-fraction delivery code, we are seeing increased inquiry levels, stronger pipeline development, a growing pipeline of qualified opportunities as of quarter end, and greater engagement from dermatology practices and hospital systems. We shipped 14 SRT systems during the quarter, including 10 direct sales and four placements under the Fair Deal Agreement program as well as rental arrangements. Importantly, these shipments reflect continued progress in broadening our customer base and meaningfully reducing historical customer concentration. We were able to match our sales from Q4, which we believe we will improve upon quarter over quarter for the balance of the year and into 2027. We saw strong momentum coming out of several major dermatology conferences during the quarter where physician interest and engagement levels were among the highest we have experienced. These events continue to be a critical driver of our pipeline growth and customer education as awareness of the new reimbursement environment increases, in addition to the benefit of SRT as a non-invasive alternative to Mohs surgery. Patients are deciding more and more their preference to avoid surgery. Recurring revenue growth and the FDA plus software. Another priority is expanding recurring revenue streams tied to utilization of our installed base and new prospects. There are still groups who prefer a shared service program, as indicated by the four of 14 units shipped in Q1. We are confident this will continue to grow. Our Fair Deal Agreement program continues to be a driver of utilization-based revenue. During the quarter, treatment volumes increased 8% over 2025, and we continue to increase the number of patients. We ended the quarter with 18 active FDA sites and nine pending activations. As we have said previously, FDA placements often serve as a bridge to system ownership, and we continue to see that dynamic play out as customers better understand the economics under the new reimbursement environment. Importantly, we are now taking additional steps to expand recurring revenue through software and services. The introduction of SensusLink represents an important evolution of our model, enabling enhanced workflow, treatment documentation, and operating intelligence across our installed base, while creating a scalable recurring revenue opportunity tied to treatment activity. We view this as an important step in evolving our business model toward a more predictable and recurring revenue profile in the future. Over time, we expect recurring revenue including FDA, service, and software to represent an increasing percentage of total revenue, which historically has been about 10%. Commercial expansion and diversification. Our next priority is broadening commercial reach through access to our technology and reducing volatility by creating more ways for customers to acquire and use Sensus Healthcare, Inc. systems. We are seeing increased interest across a wider range of customers including independent dermatology practices, group networks, hospital systems, and private equity-backed platforms. To support this, we recently launched Sensus Healthcare Financial Services, which provides a streamlined pathway for customers to acquire our systems through flexible financing options. Since launch, we have begun actively engaging with prospective customers to utilize this platform and are seeing improved conversion rates on late-stage opportunities. We are also seeing a shift in customer preference towards purchase compared to prior periods where Fair Deal Agreement program participation was the primary entry point. We now have to ask the question: Why do you want to give up 50% of your revenue when one patient procedure per month represents your breakeven? Profitability. Our priority is translating stronger demand, a growing recurring revenue base, and disciplined expense management into profitability. We are entering this new phase with a strong balance sheet, including $18.3 million in cash and no debt. While our first quarter results continue to reflect transition away from historical customer concentration, we believe the combination of improved reimbursement, a more diversified customer base, expanding recurring revenue streams, and disciplined expense management positions us to deliver improved financial performance over the balance of 2026 with the objective of achieving full-year profitability. With that, I will turn the call over to Michael to provide more detail on our commercial execution and growth initiatives. Michael? Michael J. Sardano: Thanks, Joe. I will focus on how our commercial model is evolving and how we are executing against the priorities Joe just outlined. The most important change we are seeing is that reimbursement clarity has fundamentally reshaped how customers evaluate and adopt SRT. Importantly, this is shifting SRT from a considered option to a financially actionable decision for more and more practices. Customers now have multiple pathways to adoption, including outright purchase, leasing structures, and the Fair Deal Agreement program. In the first quarter, approximately 70% of systems shipped were purchased versus FDA. Average breakeven for customers is now two patients per month, and we are seeing a higher percentage of customers electing ownership earlier in the adoption cycle. From a pipeline perspective, we are seeing increased conversion activity across the board as customers move from evaluation to decision making. A key driver of this momentum has been our participation in several major dermatology conferences during the quarter. These conferences generated new leads, physician engagements and demos, and a meaningful increase in follow-up activity and site evaluations. Importantly, our decision to refine our conference and trade show strategy to prioritize high-yield events where purchasing decisions are actively being evaluated is paying off in our pipeline. Physicians are becoming more aware of the new CPT codes and improved economics of SRT. On the recurring revenue side, our focus is on increasing utilization across the installed base and expanding monetization through additional capabilities. SensusLink is an important part of this strategy, as it enables us to bring advanced functionality to both new and existing systems while also creating a pathway for ongoing service and software revenue tied to treatment workflows. On the installed base, total SRT systems now stand at approximately 965 units globally. We expect the rollout of SensusLink, which provides advanced operating capabilities to our SRT-100 installed base, to begin to take shape and increase interest in SRT significantly this year. Over time, we believe this will support increased utilization, improve customer retention, and create a recurring revenue stream tied directly to system usage. International markets continue to represent an important growth opportunity for Sensus Healthcare, Inc. We are seeing continued demand in key markets such as China and expect additional diversification over time as we expand into new regions. International sales also provide attractive margin characteristics due to lower servicing requirements. Domestically, we are taking a disciplined approach to scaling our sales organization in 2026. Our focus is on expanding selectively, increasing market education, and improving conversion efficiency. Overall, the underlying performance of our business will continue to improve as a combination of reimbursement clarity, expanded adoption pathways, and a more diversified commercial strategy positions us well for sustained growth and profitability. With that, I will turn the call over to Javier for a review of the financials. Javier Rampolla: Thank you, Michael, and good afternoon, everyone. I will briefly review our financial results for 2026, starting with revenue. Revenue for the quarter was $3.4 million compared to $8.3 million in the prior-year period. The year-over-year decrease was primarily driven by the absence of sales to our historically largest customer as well as a lower number of total units shipped. As a reminder, the prior-year period included a significant number of direct sales to that customer. In the current quarter, we had no sales to that customer, which reflects our ongoing transition towards a more diversified customer base. Importantly, excluding sales to that customer in the prior-year period, revenue increased compared to $2.7 million, demonstrating underlying growth driven by a broader mix of customers. In addition, a portion of systems shipped during the quarter were under the Fair Deal Agreement program and rental arrangements, where revenue is recognized over the term of the agreement rather than at the time of shipment. As a result, these placements contribute to revenue over time rather than upfront. Turning to cost of sales. Cost of sales was $2.4 million compared to $4.0 million in the prior-year period. The decrease was primarily driven by lower unit volumes, again reflecting the absence of sales to our historically largest customer, as well as the shift towards FDA and rental placements. Moving to gross profit and margin. Gross profit was $1.0 million compared to $4.4 million in the prior-year period, and gross margin was 29.2% compared to 52.2% in 2025. The decline in gross margin was primarily driven by product mix. This includes a higher proportion of international shipments, which carry lower average selling prices, as well as costs associated with the new system placements under our Fair Deal Agreement program. As utilization increases, these arrangements are expected to contribute more meaningfully to revenue and margin over future periods. Turning to operating expenses. General and administrative expense was $2.0 million compared to $2.2 million in the prior-year period, with the decrease primarily driven by lower professional fees. Selling and marketing expenses were $1.7 million compared to $2.2 million in the prior-year period. The decrease was primarily due to our decision to lower trade show-related spending to focus on events with the highest potential for sales generation. Research and development expense was $1.6 million compared to $2.6 million in the prior-year period. The decrease reflects lower lobbying costs related to reimbursement efforts as well as reductions in headcount and product development spending for next-generation systems. Adjusted EBITDA for 2026 was negative $4.2 million compared with negative $2.5 million for 2025. Adjusted EBITDA, a non-GAAP financial measure, is defined as earnings before interest, taxes, depreciation, amortization, and stock compensation expense. Please see our earnings release issued earlier today for a reconciliation of GAAP and non-GAAP financial measures. Other income was $0.1 million compared to $0.2 million in the prior-year period and relates primarily to interest income. Net loss for the quarter was $2.6 million, or $0.16 per share, consistent with the prior-year period. Finally, we continue to maintain a strong balance sheet, ending the quarter with $18.3 million in cash, no debt, and inventory of $16.5 million, an increase from $14.6 million as of 12/31/2025. This inventory level positions us to continue to meet demand in the coming quarters for both direct and for placements under the Fair Deal Agreement program. Before I turn the call back to Joe, I would like to provide some perspective on how we are thinking about the remainder of the year. We expect second quarter revenue to be higher than first quarter, and we also expect revenue in the second half of the year to be higher than the first half as we continue to build on the momentum we are seeing in our pipeline and customer engagement. From a margin perspective, as discussed earlier, first quarter gross profit and margin reflect the impact of product mix, including a higher proportion of international shipments, as well as costs associated with new system placements under our Fair Deal Agreement program. As utilization under these arrangements increases and revenue is recognized over time, we expect these dynamics to evolve over the course of the year. With that, I will turn the call back to Joe. Joseph C. Sardano: Thank you, Javier and Michael, for those updates. Before we open the call for questions, I want to reiterate that we believe SRT is increasingly being viewed as a compelling noninvasive treatment option that allows practices to expand patient access, improve workflow efficiency, and offer an alternative for treating patients with non-melanoma skin cancer. The new dedicated CPT codes for superficial radiotherapy significantly improve physician reimbursement and support broader adoption of our technology while benefiting patients with certainty of coverage for noninvasive treatment options. As we move through 2026, we remain focused on executing against our five priorities: education and training, accelerating customer adoption, expanding recurring revenue, broadening our commercial reach, and driving Sensus Healthcare, Inc. toward profitability. We believe we are still in the early stages of this transition and look forward to updating you on our progress throughout the year. Thank you for your continued support. Operator: We will now open the call for questions. Your first question today comes from Anthony V. Vendetti with Maxim Group. Anthony V. Vendetti: Joe, how are you doing? Hey, Mike. My first question is a two-part question. Your largest customer, which I think you had 15 units sold to in 2025, so with zero in first quarter 2026, it is not too surprising that revenue is down over 50%. When you said second quarter should be higher than first quarter, should we look at your largest customer, who is not buying any units right now, as upside if they come back? Are you internally assuming they do not come back, and if they do, it is upside? And then I have a follow-up question. Joseph C. Sardano: If they do come back, it is upside. We have not included them in our model for this year, but that does not mean they cannot figure out the new model they have to come up with so that they can remain strong in the market. Anthony V. Vendetti: Okay. So it is still a possibility. Then, with the new CPT codes that took effect January 1 and the approximately 300% increase in the per-fraction delivery code, are you seeing that translate into shorter sales cycles or a bigger pipeline of new business? If there is a pipeline, has it just not yet converted into revenue and you expect it to in time, or is it taking a while for the pipeline to build even though the code has significantly increased? Joseph C. Sardano: I will give you an overview, and then I will let Michael handle it since he was responsible for working directly with CMS to gain those codes. What we are seeing on an overall basis is that interest has increased significantly because of the dedicated and guaranteed coding system for SRT for dermatology. In the past, that did not exist. They were orphan codes that mostly came from ASTRO, and these new codes are specific to dermatology and to SRT. So we are excited for all of that. Regarding the interest from the field, more and more offices are contemplating bringing SRT into their practice because of those codes. Very clear, very obvious. Many are deciding whether they want to go with an FDA, an outright purchase, or a fair market value lease. They are taking it seriously because now all of these sites can consider this a long-term decision for their practice since those codes are in place. Michael? Michael J. Sardano: Sure. Thanks, Anthony. Great question. Joe covered most of it. The thing I will add is that on January 1, 2026, all of the codes took effect, but when it comes to coding and reimbursement, you do not know whether you are going to get paid or how the structure works until after you bill that patient and wait the four to six weeks. So people were not able to see the EOBs of these patients until mid-February to early March when you started treating patients. With those EOBs coming in, now we have actual proof, like Joe said, that we are getting paid. Private insurance, Medicare, Medicaid, CMS, etc., are paying these new codes the way they are supposed to. Now that we have that black-and-white proof, it is in our sales team’s hands, and we are giving it to the market. A big point we did not touch on is that our largest show of the year, AAD, took place March 27 to 31. Those leads could not close in Q1, so they are moving into Q2. I am very confident going into Q2 compared to Q1. As I said on the call, we expect to continue to grow and improve throughout the year, quarter over quarter. As Javier mentioned, we have more recurring revenue shipments than we have ever had before. From an FDA standpoint and also this rental model, as we get 10 rental contracts, then 30, then 40 or 50, we are quickly transitioning to a more recurring revenue base that will require patience. We are transitioning in a way investors have asked for over the last ten years—more recurring revenue, not solely focused on one revenue source—and now we are achieving that. I think we will see improvement on that. Anthony V. Vendetti: That makes sense. As best you can, can you timeline it for us? As you build this pipeline of recurring revenue and the Fair Deal Agreement, do you feel like, whether this quarter, next quarter, or sometime in 2026, you lap that pipeline and then it is easier to see revenues grow? Is there an inflection point you are looking for? Michael J. Sardano: As the education continues to roll out, for instance, we just had two or three more meetings this past April with large roll-up groups in addition to Florida-, Arizona-, and California-based meetings. As that happens, you are going to see education expand. The black-and-white codes greatly help us. This is the first time in our sixteen years that I have been able to go in a room and tell a doctor that these are black-and-white codes with no gray area. As that comes in, you will see a lot of people who were not interested over the last ten years now become interested because their accountants and lawyers can make sense of it. That is about education. The longer you give us, the more we can educate, and more people will adopt SRT. It is here to stay now. CMS has given us exclusive codes for SRT for the first time ever. We do not have to go to Washington as much anymore, which is good for time and money. We are excited. The sales team is fired up. We have already hired three more salespeople into territories—some new and some rehires. We are very excited to keep going. Joseph C. Sardano: Let me add one thing to your question about the recurring revenue piece. One of the codes involves radiation physics and the consults for radiation physics. This code has to be applied to every patient, and our introduction of SensusLink is a main focus for our customer base. They can charge that code once per week. For example, if their protocol uses 20 treatments at two treatments per week over ten weeks, this radiation physics code can be charged at an average of $93.85 per week across the country. That is ten weeks of treatment, or about $930. With our software, we will be sharing that revenue with our customers. The only way that they can access that reimbursement is through SensusLink. That is an important piece of our business that we did not have before. Anthony V. Vendetti: When did SensusLink officially go live? Joseph C. Sardano: It is live now and performing in several accounts already. Anthony V. Vendetti: Great. That was great color. Thanks. I will hop back in the queue. Appreciate it. Michael J. Sardano: Thanks, Anthony. Operator: Seeing no additional questions, this concludes our question and answer session. I would like to turn the conference back over to management for any closing remarks. Joseph C. Sardano: I think everybody heard where we are headed this year. We believe we are going to have a profitable year, with each and every quarter being better than the previous. We have a very solid start to the year and are looking for increased revenues throughout. With that being said, we look forward to a very successful second quarter and to talking to you again at the next earnings call. Thank you so much. Operator: The conference has now concluded. Thank you for attending today's presentation. You may now disconnect. Before you buy stock in Sensus Healthcare, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Sensus Healthcare wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $476,034!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,274,109!* Now, it’s worth noting Stock Advisor’s total average return is 974% — a market-crushing outperformance compared to 206% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of May 7, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Sensus (SRTS) Q1 2026 Earnings Transcript was originally published by The Motley Fool

Dedicated CPT Codes for Superficial Radiotherapy (SRT) Now Effective, Driving Increased Customer Activity, Customer Diversification and Improved Physician Economics Sales Pipeline and Financing Activity Strengthen Following Reimbursement Clarity Expansion of Installed Base and Recurring Revenue Growth Driving Advancement Towards Profitability Exited the Quarter with $18.3 Million in Cash and No Debt BOCA RATON, Fla., May 07, 2026--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended March 31, 2026. Highlights included: Revenue of $3.4 million compared to $8.3 million for the three months ended March 31, 2025. Excluding sales to the Company’s historically largest customer, revenue increased from $2.7 million in the quarter ended March 31, 2025. Shipped 14 SRT systems (10 direct sales and 4 placements under Fair Deal Agreement program and rental arrangements) compared to 30 systems shipped in the prior-year period (21 direct sales and 9 Fair Deal Agreement program placements). None of the quarter’s direct sales were to the Company’s historically largest customer, compared to 15 in the prior-year period. Dedicated CPT Codes for SRT and IG-SRT, effective January 1, 2026, provide reimbursement certainty for the treatment of non-melanoma skin cancer. Company experienced increased inquiry levels, stronger pipeline activity, and greater customer engagement from dermatology practices and hospitals following implementation of new CPT Codes. Continued expansion of the Fair Deal Agreement program, with treatment volumes increasing 8% over the first quarter of 2025. 18 active sites and 9 sites pending activation as of March 31, 2026. Launched Sensus Healthcare Financial Services to further support customer acquisition and financing flexibility. Introduced Sensus Link, providing advanced operating capabilities to the SRT-100™ installed base. Ended the quarter with $18.3 million in cash and cash equivalents and no debt. Management Commentary "During the first quarter, we began our efforts in educating and training our existing customer base as well as our many new prospects. We are seeing the benefits of the dedicated CPT Codes for superficial radiotherapy move from concept to commercial reality," said Joseph Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. "With these codes now in effect, physicians have greater reimbursement visibility and substantially improved economics to offer SRT and IG-SRT for the treatment of non-melanoma skin cancer, including an approximately 300% increase in the per-fraction delivery code. We believe this will meaningfully improve the quality of our sales pipeline, increase customer engagement, shorten the decision-making process for many prospective customers and, importantly, support continued diversification of our customer base. "We also continued to grow our customer base through expansion of our Fair Deal Agreement program, the launch of Sensus Healthcare Financial Services, and increased interest among independent practices, group networks, and hospitals that historically had not adopted SRT. In addition, the introduction of Sensus Link represents an important step in our strategy to expand higher-margin recurring revenue streams by bringing enhanced workflow, treatment documentation and operating intelligence capabilities to our installed base. "As we enter this new reimbursement environment, we are focused on five priorities for 2026: education and training, accelerating customer adoption, expanding recurring revenue, broadening our commercial reach, and driving Sensus toward profitability," concluded Sardano. First Quarter 2026 Financial Results Revenues were $3.4 million compared to $8.3 million for the three months ended March 31, 2025. The decrease in revenue was primarily due to the absence of sales to the Company’s historically largest customer and a lower number of units shipped. In addition, some systems placed during the quarter were under Fair Deal Agreement program and rental arrangements, for which revenue is recognized over the term of the agreement rather than at the time of shipment. Excluding sales to the Company’s historically largest customer for the three months ended March 31, 2025, revenue increased compared to $2.7 million, reflecting continued progress in diversifying the customer base. Cost of sales was $2.4 million compared to $4.0 million for the prior-year period. The decrease was primarily driven by a lower number of units sold, reflecting the absence of sales to the Company’s historically largest customer in the current quarter, as well as a shift toward placements under Fair Deal Agreement program and rental arrangements. Gross profit was $1.0 million compared to $4.4 million for the prior-year period. Gross margin was 29.2% in the first quarter of 2026, compared to 52.2% in the corresponding period in 2025. The decrease in gross profit and margin was primarily driven by product mix, including a higher proportion of international shipments, which carry lower average selling prices, and costs associated with new system placements under the Company’s Fair Deal Agreement program, under which revenue is recognized over the term of the agreement. General and administrative expense was $2.0 million compared to $2.2 million for the three months ended March 31, 2025. The net decrease in general and administrative expense was primarily due to lower professional fees. Selling and marketing expense was $1.7 million compared to $2.2 million for the three months ended March 31, 2025, a decrease of $0.5 million. The decrease was primarily driven by a reduction in tradeshow expenses. Research and development expense was $1.6 million compared to $2.6 million for the three months ended March 31, 2025, a decrease of $1.0 million. The decrease was primarily due to reductions in lobbying costs related to billing code reimbursement, headcount, and product development for next generation systems. Adjusted EBITDA for the first quarter of 2026 was negative $4.2 million, compared with negative $2.5 million for the first quarter of 2025. Adjusted EBITDA, a non-GAAP financial measure, is defined as earnings before interest, taxes, depreciation, amortization and stock-compensation expense. Please see below for a reconciliation between GAAP and non-GAAP financial measures, and the reasons these non-GAAP financial measures are provided. Other income of $0.1 and $0.2 million for the three months ended March 31, 2026, and 2025, respectively relates primarily to interest income. Net loss was $2.6 million, or $0.16 per share, compared with net loss of $2.6 million, or $0.16 per share, for the three months ended March 31, 2025. Cash and cash equivalents were $18.3 million as of March 31, 2026, compared with $22.1 million as of December 31, 2025. The Company had no outstanding borrowings under its revolving line of credit at March 31, 2026. Prepaid inventory was $2.5 million compared with $1.6 million as of December 31, 2025. Inventories were $16.5 million compared with $14.6 million as of December 31, 2025. Conference Call and Webcast Sensus Healthcare will host an investment community conference call today beginning at 4:30 p.m. Eastern time during which management will discuss these financial results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register can access the conference call by dialing 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). Please ask the operator to be connected to the Sensus Healthcare conference call. The call will be webcast live and can be accessed at this link or in the Investor Relations section of the Company’s website at www.sensushealthcare.com. Use of Non-GAAP Financial Information This press release contains supplemental financial information determined by methods other than in accordance with accounting principles generally accepted in the United States (GAAP). Sensus Healthcare management uses Adjusted EBITDA, a non-GAAP financial measure, in its analysis of the Company’s performance. Adjusted EBITDA should not be considered a substitute for GAAP basis measures, nor should it be viewed as a substitute for operating results determined in accordance with GAAP. Non-GAAP financial measures are not formally defined by GAAP, and other entities may use calculation methods that differ from those used by Sensus Healthcare. As a complement to GAAP financial measures, management believes that Adjusted EBITDA assists investors who follow the practice of some investment analysts who adjust GAAP financial measures to exclude items that may obscure underlying performance and distort comparability. A reconciliation of the GAAP net loss to Adjusted EBITDA is provided in the schedule below. About Sensus Healthcare Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com. Forward-Looking Statements This press release includes statements that are, or may be deemed, "forward-looking statements." In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately," "potential" or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus Healthcare, Inc., our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release as a result of the following factors, among others: the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries, including ongoing geopolitical tensions between the U.S. and China; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation (including the possibility of tariffs and fluctuations in tariffs on equipment we export or materials we import), or other aspects of our business; the performance of the Company’s information technology systems and its ability to maintain data security; the possibility that inflationary pressures continue to impact our sales; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission. To date, the geopolitical uncertainties other than those relating to China have not had any significant impact on our business, but we continue to monitor developments and will address them in future filings, if applicable. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully the introductory note regarding forward-looking statements and the factors described in the "Risk Factors" section included in our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business. View source version on businesswire.com: https://www.businesswire.com/news/home/20260507781798/en/ Contacts Investor Relations Contact Leigh Salvo New Street Investor Relations [email protected]